🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Role of the Fibroblast Activation Protein (FAP) as Biomarker of Fibrotic Lung Diseases

RecruitingPhase 2Ages 18 Years - anyAllErasme University Hospital
NCT06189820 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

To evaluate the effect of an anti-fibrotic treatment initiation on the fibrotic activity as assessed by FAPI PET/CT.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines Exclusion Criteria: * Pregnant or nursing patients * Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * Patients with an active lung neoplasm or any active neoplasm for blood samples
💊

What it tests

  • FAPI PET/CT
📍

Where

1 site
Medecine
Brussels, Belgium
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy